Cognition Therapeutics Stock Buy Hold or Sell Recommendation
| CGTX Stock | USD 0.40 0.01 2.44% |
Given the investment horizon of 90 days and your typical level of risk aversion, our recommendation regarding Cognition Therapeutics is 'Strong Sell'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Cognition Therapeutics given historical horizon and risk tolerance towards Cognition Therapeutics. When Macroaxis issues a 'buy' or 'sell' recommendation for Cognition Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Cognition Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Cognition Stock please use our How to Invest in Cognition Therapeutics guide. In addition, we conduct extensive research on individual companies such as Cognition and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Cognition Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Cognition |
Execute Cognition Therapeutics Buy or Sell Advice
The Cognition recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Cognition Therapeutics. Macroaxis does not own or have any residual interests in Cognition Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Cognition Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Cognition Therapeutics Trading Alerts and Improvement Suggestions
| Cognition Therapeutics generated a negative expected return over the last 90 days | |
| Cognition Therapeutics has high historical volatility and very poor performance | |
| Cognition Therapeutics has some characteristics of a very speculative penny stock | |
| Cognition Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (25.79 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Cognition Therapeutics currently holds about 46.61 M in cash with (16.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.94, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Cognition Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Cognition Therapeutics Analysis Correlates Biomarker Changes withCognitive Benefit in Alzheimers Population |
Cognition Therapeutics current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Cognition analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Cognition analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Average Consensus Strong Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Cognition Therapeutics Returns Distribution Density
The distribution of Cognition Therapeutics' historical returns is an attempt to chart the uncertainty of Cognition Therapeutics' future price movements. The chart of the probability distribution of Cognition Therapeutics daily returns describes the distribution of returns around its average expected value. We use Cognition Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Cognition Therapeutics returns is essential to provide solid investment advice for Cognition Therapeutics.
| Mean Return | -0.66 | Value At Risk | -10.34 | Potential Upside | 8.89 | Standard Deviation | 6.30 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Cognition Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Cognition Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Cognition Therapeutics, soars without any apparent reason? This usually happens because many institutional investors are aggressively trading Cognition Therapeutics back and forth among themselves.
| Shares | Renaissance Technologies Corp | 2024-09-30 | 88.7 K | Corsair Capital Management Llc | 2024-06-30 | 77.4 K | Bridgeway Capital Management, Llc | 2024-09-30 | 76.7 K | State Street Corp | 2024-06-30 | 62.8 K | Texas Capital Bank Wealth Management Services Inc | 2024-06-30 | 55.4 K | Fca Corp | 2024-09-30 | 51.5 K | Circle Wealth Management, Llc | 2024-09-30 | 48.8 K | Northern Trust Corp | 2024-09-30 | 47.5 K | Castle Wealth Management Llc | 2024-09-30 | 43.4 K | Vanguard Group Inc | 2024-09-30 | 1.2 M | Alyeska Investment Group, L.p. | 2024-09-30 | 500 K |
Cognition Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Cognition Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Cognition Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Cognition stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.83 | |
β | Beta against Dow Jones | 1.43 | |
σ | Overall volatility | 6.29 | |
Ir | Information ratio | -0.12 |
Cognition Therapeutics Volatility Alert
Cognition Therapeutics is displaying above-average volatility over the selected time horizon. Cognition Therapeutics is a potential penny stock. Although Cognition Therapeutics may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Cognition Therapeutics. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Cognition instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Cognition Therapeutics Fundamentals Vs Peers
Comparing Cognition Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Cognition Therapeutics' direct or indirect competition across all of the common fundamentals between Cognition Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Cognition Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Cognition Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Cognition Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Cognition Therapeutics to competition |
| Fundamentals | Cognition Therapeutics | Peer Average |
| Return On Equity | -1.08 | -0.31 |
| Return On Asset | -0.94 | -0.14 |
| Current Valuation | (4.9 M) | 16.62 B |
| Shares Outstanding | 41.55 M | 571.82 M |
| Shares Owned By Insiders | 0.54 % | 10.09 % |
| Shares Owned By Institutions | 24.53 % | 39.21 % |
| Number Of Shares Shorted | 722.95 K | 4.71 M |
| Price To Book | 1.14 X | 9.51 X |
| EBITDA | (25.51 M) | 3.9 B |
| Net Income | (25.79 M) | 570.98 M |
| Cash And Equivalents | 46.61 M | 2.7 B |
| Cash Per Share | 1.94 X | 5.01 X |
| Total Debt | 1.24 M | 5.32 B |
| Debt To Equity | 0.02 % | 48.70 % |
| Current Ratio | 4.20 X | 2.16 X |
| Book Value Per Share | 0.76 X | 1.93 K |
| Cash Flow From Operations | (16.02 M) | 971.22 M |
| Short Ratio | 1.07 X | 4.00 X |
| Earnings Per Share | (0.96) X | 3.12 X |
| Target Price | 6.2 | |
| Number Of Employees | 25 | 18.84 K |
| Beta | 1.34 | -0.15 |
| Market Capitalization | 16.53 M | 19.03 B |
| Total Asset | 35.16 M | 29.47 B |
| Retained Earnings | (141.19 M) | 9.33 B |
| Working Capital | 24.05 M | 1.48 B |
| Net Asset | 35.16 M |
Note: Acquisition by Wallace Peggy of 8335 shares of Cognition Therapeutics at 1.92 subject to Rule 16b-3 [view details]
Cognition Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Cognition . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 0.0732 | |||
| Daily Balance Of Power | (0.33) | |||
| Rate Of Daily Change | 0.98 | |||
| Day Median Price | 0.4 | |||
| Day Typical Price | 0.4 | |||
| Market Facilitation Index | 0.03 | |||
| Period Momentum Indicator | (0.01) |
About Cognition Therapeutics Buy or Sell Advice
When is the right time to buy or sell Cognition Therapeutics? Buying financial instruments such as Cognition Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Cognition Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Aircraft Thematic Idea Now
Aircraft
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Aircraft theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Aircraft Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Cognition Stock Analysis
When running Cognition Therapeutics' price analysis, check to measure Cognition Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cognition Therapeutics is operating at the current time. Most of Cognition Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cognition Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cognition Therapeutics' price. Additionally, you may evaluate how the addition of Cognition Therapeutics to your portfolios can decrease your overall portfolio volatility.